Persistence of antibody to hepatitis B and protection from disease among Alaska Natives immunized at birth

Pediatric Infectious Disease Journal

Volumn 24, Issue 9, 2005, Pages 786-792

  Dentinger, Catherine M ^a   McMahon, Brian J ^a,b   Butler, Jay C ^a   Dunaway, Charlotte E ^a   Zanis, Carolyn L ^a   Bulkow, Lisa R ^a   Bruden, Dana L ^a   Nainan, Omana V ^a   Khristova, Marina L ^a   Hennessy, Thomas W ^a   Parkinson, Alan J ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

Author keywords

Alaska Natives; Hepatitis B vaccine; Infants

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPTAVAX; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT VACCINE; VIRUS DNA;

ANTIBODY PRODUCING CELL; ARTICLE; CHILD; CHRONIC DISEASE; CONCENTRATION RESPONSE; DOSE RESPONSE; ESKIMO; EVALUATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 24944459721     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000176617.63457.9f     Document Type: Article

References (37)

1. Schreeder MT, Bender TR, McMahon BJ, et al. Prevalence of hepatitis B in selected Alaskan Eskimo villages. Am J Epidemiol. 1983;118: 543-549.
2. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol. 1993;138:544-549.
3. McMahon BJ, Alward WM, Hall DB, et al. Acute hepatitis B infection: relationship of age to the clinical expression of disease and the subsequent development of the carrier state. J Infect Dis. 1985;151:599-603.
4. McMahon BJ, Heyward WL, Ritter D, et al. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaska Natives. Lancet. 1987;1134-1136.
5. McMahon BJ, Hoick P, Bulkow L, Snowball M. Serologie and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759-768.
6. Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis. 2000;181:413-418.
7. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR. 1991;40 (RR-13):1-25.
8. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1988: implications for vaccination programs. J Infect Dis. 2002;185:713-719.
9. Centers for Disease Control and Prevention. Notice to readers: FDA approval of change in pediatric formulation for Recombivax HB. MMWR. 1999;48:34-35.
10. Hollinger FB, Adam E, Heiburg D, Melnick JL. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis 1981 International Symposium. Philadelphia: Franklin Institute Press, 1982;451-466.
11. Nainan OV, Khristova M, Byun KS, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol. 2002;68:319-327.
12. Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods. 1996;61:127-134.
13. Devereux JP, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 1984;12:387-395.
14. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology. 1999;29:924-927.
15. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J. 2003;22:157-163.
16. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319-1325.
17. Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr. 1995;126:716-721.
18. Mele A, Tancredi F, Romano L, et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis. 2001;184:905-908.
19. Resti M, Azzari C, Mannelli F, Rossi ME, Lionetti P, Vierucci A. Ten-year follow-up of neonatal hepatitis B immunization: are booster jrijections indicated? Vaccine. 1997;15:1338-1340.
20. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999; 29:954-959.
21. Chotard M, Inskip HM, Hall AJ, et al. The Gambia hepatitis intervention study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis. 1992;166:764-768.
22. Coursaget P, Leboulleux D, Soumare M, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol. 1994;21:250-254.
23. McMahon BJ, Bruden DA, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142:333-341.
24. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis. 1993;17:475-479.
25. Young BW, Lee SS, Lim WL, Yeoh EK. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat. 2003;10:23-30.
26. Seto D, West DJ, Ioli VA. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J. 2002;21:793-795.
27. Boxall EH, Sira JA, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190:1264-1269.
28. Mahoney FJ, Woodruff B, Auerbach S, et al. Progress on the elimination of hepatitis B virus transmission in Micronesia and American Samoa. Pacific Health Dialog. 1996;3:140-146.
29. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: results of a 10-year study. J Infect Dis. 1997;175:674-677.
30. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis. 1998;26:933-937.
31. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325-329.
32. Fortuin M, Karthigesu V, Howard CA, Hoare S, Mendy M, Whittle HC. Breakthrough infections and identification of a viral variant in Gambian children with hepatitis B vaccine. J Infect Dis. 1994;169: 1374-1376.
33. Milne A, Hopkirk N, Moyes CD. Hepatitis B vaccination in children: persistence of immunity at 9 years. J Med Virol. 1994;44:113-114.
34. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209-214.
35. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996;11:1019-1027.
36. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877-885.
37. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650-655.